Response to sunitinib in combination with proton beam radiation in a patient with chondrosarcoma: A case report

Journal of Medical Case Reports

Volumn 6, Issue , 2012, Pages

  Dallas, Jennifer ^a   Imanirad, Iman ^a   Rajani, Rajiv ^b   Dagan, Roi ^b   Subbiah, Sukanthini ^a   Gaa, Rebecca ^a   Dwarica, Wayne A ^a   Ivey, Alison M ^a   Zlotecki, Robert A ^b   Malyapa, Robert ^b   Indelicato, Danny J ^b   Scarborough, Mark T ^b   Reith, John D ^b   Gibbs, C Parker ^b   Dang, Long H ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; SUNITINIB;

ACNE; ADULT; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER RECURRENCE; CASE REPORT; CHONDROSARCOMA; CLEAR CELL CARCINOMA; CLEAR CELL CHONDROSARCOMA; DIARRHEA; DRUG DOSE REDUCTION; HIP PAIN; HUMAN; LUNG METASTASIS; MALE; PELVIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTON RADIATION; RADIATION DOSE FRACTIONATION; RASH; TREATMENT RESPONSE;

EID: 84856253146     PISSN: None     EISSN: 17521947     Source Type: Journal    
DOI: 10.1186/1752-1947-6-41     Document Type: Article

References (22)

1. The clinical approach towards chondrosarcoma. Gelderblom H, Hogendoorn PC, Dijkstra SD, van Rijswijk CS, Krol AD, Taminiau AH, Bovee JV, Oncologist 2008 13 320 329 10.1634/theoncologist.2007-0237 18378543 (Pubitemid 351679908)
2. Update on chondrosarcomas. Chow WA, Curr Opin Oncol 2007 19 371 376 10.1097/CCO.0b013e32812143d9 17545802 (Pubitemid 46883528)
3. Surmounting chemotherapy and radioresistance in chondrosarcoma: molecular mechanisms and therapeutic targets. Onishi AC, Hincker AM, Lee FY, Sarcoma 2011 2011 381564 21234363
4. The clinical management of chondrosarcoma. Riedel RF, Larrier N, Dodd L, Kirsch D, Martinez S, Brigman BE, Curr Treat Options Oncol 2009 10 94 106 10.1007/s11864-009-0088-2 19238552
5. Treatment and outcome of recurrent pelvic chondrosarcoma. Weber KL, Pring ME, Sim FH, Clin Orthop Relat Res 2002 397 19 28 11953591 (Pubitemid 34442011)
6. A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet-derived growth factor receptor-alpha or -beta: An Italian Sarcoma Group study. Grignani G, Palmerini E, Stacchiotti S, Boglione A, Ferraresi V, Frustaci S, Comandone A, Casali PG, Ferrari S, Aglietta M, Cancer 2011 117 826 831 10.1002/cncr.25632 20925044
7. Phase II clinical trial of imatinib mesylate in therapy of KIT and/or PDGFRalpha-expressing Ewing sarcoma family of tumors and desmoplastic small round cell tumors. Chao J, Budd GT, Chu P, Frankel P, Garcia D, Junqueira M, Loera S, Somlo G, Sato J, Chow WA, Anticancer Res 2010 30 547 552 20332468
8. Malignant peripheral nerve sheath tumour (MPNST): the clinical implications of cellular signalling pathways. Katz D, Lazar A, Lev D, Expert Rev Mol Med 2009 11 30 19835664
9. Successful PDGFR-{alpha}/{beta} targeting with imatinib in uterine sarcoma. Trojan A, Montemurro M, Kamel M, Kristiansen G, Ann Oncol 2009 20 1898 1899 10.1093/annonc/mdp431 19748901
10. Coactivated platelet-derived growth factor receptor {alpha} and epidermal growth factor receptor are potential therapeutic targets in intimal sarcoma. Dewaele B, Floris G, Finalet-Ferreiro J, Fletcher CD, Coindre JM, Guillou L, Hogendoorn PC, Wozniak A, Vanspauwen V, Schoffski P, Marynen P, Vandenberghe P, Sciot R, Debiec-Rychter M, Cancer Res 2010 70 7304 7314 10.1158/0008-5472.CAN- 10-1543 20685895
11. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. George S, Merriam P, Maki RG, van den Abbeele AD, Yap JT, Akhurst T, Harmon DC, Bhuchar G, O'Mara MM, D'Adamo DR, Morgan J, Schwartz GK, Wagner AJ, Butrynski JE, Demetri GD, Keohan ML, J Clin Oncol 2009 27 3154 3160 10.1200/JCO.2008.20.9890 19451429
12. PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma. Taniguchi E, Nishijo K, McCleish AT, Michalek JE, Grayson MH, Infante AJ, Abboud HE, Legallo RD, Qualman SJ, Rubin BP, Keller C, Oncogene 2008 27 6550 6560 10.1038/onc.2008.255 18679424
13. The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Shimizu A, O'Brien KP, Sjoblom T, Pietras K, Buchdunger E, Collins VP, Heldin CH, Dumanski JP, Ostman A, Cancer Res 1999 59 3719 3723 10446987 (Pubitemid 29381878)
14. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. McArthur GA, Demetri GD, van Oosterom A, Heinrich MC, Debiec-Rychter M, Corless CL, Nikolova Z, Dimitrijevic S, Fletcher JA, J Clin Oncol 2005 23 866 873 10.1200/JCO.2005.07.088 15681532 (Pubitemid 46224187)
15. PDGFRalpha, PDGFRbeta and KIT expression/activation in conventional chondrosarcoma. Lagonigro MS, Tamborini E, Negri T, Staurengo S, Dagrada GP, Miselli F, Gabanti E, Greco A, Casali PG, Carbone A, Pierotti MA, Pilotti S, J Pathol 2006 208 615 623 10.1002/path.1945 16470538
16. Kinome profiling of chondrosarcoma reveals SRC-pathway activity and dasatinib as option for treatment. Schrage YM, Briaire-de Bruijn IH, de Miranda NF, van Oosterwijk J, Taminiau AH, van Wezel T, Hogendoorn PC, Bovee JV, Cancer Res 2009 69 6216 6222 10.1158/0008-5472.CAN-08-4801 19602594
17. Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies. Papaetis GS, Syrigos KN, BioDrugs 2009 23 377 389 10.2165/11318860-000000000-00000 19894779
18. A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities. Christensen JG, Ann Oncol 2007 18 Suppl 10 3 10 17761721
19. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA, N Engl J Med 2007 356 115 124 10.1056/NEJMoa065044 17215529 (Pubitemid 46089672)
20. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG, Lancet 2006 368 1329 1338 10.1016/S0140-6736(06)69446-4 17046465 (Pubitemid 44528723)
21. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Schueneman AJ, Himmelfarb E, Geng L, Tan J, Donnelly E, Mendel D, McMahon G, Hallahan DE, Cancer Res 2003 63 4009 4016 12873999 (Pubitemid 36917920)
22. Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary response. Kao J, Packer S, Vu HL, Schwartz ME, Sung MW, Stock RG, Lo YC, Huang D, Chen SH, Cesaretti JA, Cancer 2009 115 3571 3580 10.1002/cncr.24412 19536893